The objective of this contract is to provide the NCI with the Phase I, Pharmacokinetic and Phase II/III clinical evaluations of investigational new drugs. Specifically the Contractor shall 1) define the acute toxicities of new anticancer agents in patients with advanced cancer; 2) define the dose of each agent which can be safely given in subsequent Phase II studies of drug activity; 3) provide information on the pharmacologic characteristics (absorption, distribution, metabolism and elimination) of selected antitumor agents; 4) explore the potential uses of pharmacokinetic analysis for optimizing scheduling and dose escalation procedures in a Phase I trial; 5) determine the spectrum of activity of new agents across a variety of human cancers in patients with minimal prior therapy; and 6) establish the role of a new compound, alone or in combination, in selected human cancers compared to standard therapy.

Agency
National Institute of Health (NIH)
Institute
Division of Cancer Treatment (NCI)
Type
Research and Development Contracts (N01)
Project #
N01CM057734-002
Application #
3613284
Study Section
Project Start
1985-06-01
Project End
1990-04-30
Budget Start
1986-02-25
Budget End
1986-11-30
Support Year
Fiscal Year
1986
Total Cost
Indirect Cost
Name
University of Maryland Baltimore
Department
Type
Schools of Medicine
DUNS #
003255213
City
Baltimore
State
MD
Country
United States
Zip Code
21201
Sridhara, R; Eisenberger, M A; Sinibaldi, V J et al. (1998) Evaluation of biomarkers of survival response in hormone-refractory prostate cancer patients treated with suramin. Cancer Epidemiol Biomarkers Prev 7:631-4
Reyno, L M; Egorin, M J; Eisenberger, M A et al. (1995) Development and validation of a pharmacokinetically based fixed dosing scheme for suramin. J Clin Oncol 13:2187-95
Sridhara, R; Eisenberger, M A; Sinibaldi, V J et al. (1995) Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy. J Clin Oncol 13:2944-53
Abrams, J S; Eiseman, J L; Melink, T J et al. (1993) Immunomodulation of interleukin-2 by cyclophosphamide: a phase IB trial. J Immunother Emphasis Tumor Immunol 14:56-64
Scher, H I; Jodrell, D I; Iversen, J M et al. (1992) Use of adaptive control with feedback to individualize suramin dosing. Cancer Res 52:64-70
Belani, C P; Egorin, M J; Abrams, J S et al. (1989) A novel pharmacodynamically based approach to dose optimization of carboplatin when used in combination with etoposide. J Clin Oncol 7:1896-902
Conley, B A; Forrest, A; Egorin, M J et al. (1989) Phase I trial using adaptive control dosing of hexamethylene bisacetamide (NSC 95580). Cancer Res 49:3436-40
Tchekmedyian, N S; Kaplan, R S; Eisenberger, M et al. (1987) Phase II study of N-methylformamide in patients with advanced colorectal cancer. Cancer Treat Rep 71:541-2
Conley, B A; Hornedo, J; Abrams, J et al. (1987) Phase II trial of 4'-deoxydoxorubicin in advanced non-small cell lung cancer. Cancer Treat Rep 71:861-2
Belani, C P; Eisenberger, M; Van Echo, D et al. (1987) Phase II study of caracemide in advanced or recurrent non-small cell lung cancer. Cancer Treat Rep 71:1099-100